(0.35%) 5 117.73 points
(0.34%) 38 368 points
(0.40%) 15 992 points
(-0.98%) $83.03
(5.51%) $2.03
(0.33%) $2 354.90
(0.46%) $27.66
(4.08%) $959.70
(-0.26%) $0.932
(-0.42%) $10.98
(-0.56%) $0.796
(1.66%) $93.40
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 8.40%
@ $329.82
発行日: 16 3月 2024 @ 00:55
リターン: 0.00%
前回のシグナル: 3月 15 - 22:30
前回のシグナル:
リターン: -0.04 %
Live Chart Being Loaded With Signals
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions...
Stats | |
---|---|
本日の出来高 | 1.28M |
平均出来高 | 971 825 |
時価総額 | 12.60B |
EPS | $0 ( 2024-02-22 ) |
次の収益日 | ( $-3.00 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -28.09 |
ATR14 | $4.03 (1.22%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-18 | Wheadon David E. | Sell | 990 | Common Stock |
2024-03-18 | Wheadon David E. | Sell | 25 000 | Option (right to buy) |
2024-03-18 | Wheadon David E. | Sell | 8 500 | Option (right to buy) |
2024-03-18 | Wheadon David E. | Sell | 5 000 | Option (right to buy) |
2024-03-18 | Wheadon David E. | Sell | 1 904 | Option (right to buy) |
INSIDER POWER |
---|
-93.83 |
Last 100 transactions |
Buy: 115 486 | Sell: 3 548 924 |
ボリューム 相関
Karuna Therapeutics Inc 相関 - 通貨/商品
Karuna Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $654 000 |
総利益: | $-1.05M (-160.09 %) |
EPS: | $-11.73 |
FY | 2023 |
収益: | $654 000 |
総利益: | $-1.05M (-160.09 %) |
EPS: | $-11.73 |
FY | 2022 |
収益: | $10.64M |
総利益: | $9.53M (89.55 %) |
EPS: | $-8.74 |
FY | 2021 |
収益: | $36.96M |
総利益: | $36.96M (100.00 %) |
EPS: | $-5.44 |
Financial Reports:
No articles found.
Karuna Therapeutics Inc
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。